Article Text

other Versions

New insulins and newer insulin regimens: a review of their role in improving glycaemic control in patients with diabetes
  1. S Gururaj Setty1,
  2. W Crasto2,
  3. J Jarvis3,
  4. K Khunti3,
  5. M J Davies1,3
  1. 1Department of Diabetes & Endocrinology, University Hospitals of Leicester NHS Trust, Leicester, UK
  2. 2Department of Diabetes & Endocrinology, George Eliot NHS Trust, Nuneaton, UK
  3. 3Diabetes Research Centre, University of Leicester, Leicester, UK
  1. Correspondence to
    Dr Sowmya Gururaj Setty, Consultant in Diabetes and Endocrinology, Northampton General Hospital NHS Trust, Cliftonville, Northampton NN1 5BD, UK; sowmyagururaj{at}


The legacy effect of early good glycaemic control in people with diabetes shows it is associated with reduction of microvascular and macrovascular complications. Insulin therapy is essential and lifesaving in individuals with type 1 diabetes and beneficial for those with type 2 diabetes who fail to achieve optimal glycaemic targets with other classes of glucose-lowering therapies. Since the introduction of insulin analogues, insulin management has changed. This follow-up review attempts to update our earlier publication from 2009 and discusses the role of new insulin analogues and newer insulin regimens. Recognising the advent of new quality and economic initiatives both in the UK and worldwide, this paper reviews current insulin prescribing and the pros and cons of prescribing analogues in comparison to the human insulins that are now gaining more acceptance in everyday clinical practice.


Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.